Cereno Scientific is granted Expanded Access by the FDA to drug candidate CS1 for rare disease pulmonary arterial hypertension
Cereno Scientific , a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company has been granted approval by the FDA for Expanded Access,...
Source: marketscreener.com